Development of A Standardized Opsonophagocytosis Killing Assay for Group B Streptococcus and Assessment in an Interlaboratory Study

The placental transfer of antibodies that mediate bacterial clearance via phagocytes is likely important for protection against invasive group B (GBS) disease. A robust functional assay is essential to determine the immune correlates of protection and assist vaccine development. Using standard reage...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 11; no. 11; p. 1703
Main Authors Leung, Stephanie, Collett, Clare F, Allen, Lauren, Lim, Suzanna, Maniatis, Pete, Bolcen, Shanna J, Alston, Bailey, Patel, Palak Y, Kwatra, Gaurav, Hall, Tom, Thomas, Stephen, Taylor, Stephen, Le Doare, Kirsty, Gorringe, Andrew
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 09.11.2023
Subjects
Animal vaccines
Antibodies
Assaying
Bacteria
Capsular polysaccharides
Cell differentiation
Consortia
correlates of protection
Flow cytometry
Group B Streptococcus
Immune clearance
Immunoassay
Immunoglobulin G
Licenses
Medical schools
Medicine
Monoclonal antibodies
neonatal antibodies
OPKA
Opsonophagocytosis
opsonophagocytosis assay
Phagocytes
Placental transfer
Polysaccharides
R&D
Reagents
Research & development
Standardization
Streptococcus
Streptococcus infections
Vaccine development
Vaccines
Denmark
Canada
United Kingdom > UK
United States > US
correlates of protection
OPKA
vaccines
Group B Streptococcus
opsonophagocytosis assay
transplacental antibodies
neonatal antibodies
Online AccessGet full text

Cover

Abstract The placental transfer of antibodies that mediate bacterial clearance via phagocytes is likely important for protection against invasive group B (GBS) disease. A robust functional assay is essential to determine the immune correlates of protection and assist vaccine development. Using standard reagents, we developed and optimized an opsonophagocytic killing assay (OPKA) where dilutions of test sera were incubated with bacteria, baby rabbit complement (BRC) and differentiated HL60 cells (dHL60) for 30 min. Following overnight incubation, the surviving bacteria were enumerated and the % bacterial survival was calculated relative to serum-negative controls. A reciprocal 50% killing titer was then assigned. The minimal concentrations of anti-capsular polysaccharide (CPS) IgG required for 50% killing were 1.65-3.70 ng/mL (depending on serotype). Inhibition of killing was observed using sera absorbed with homologous CPS but not heterologous CPS, indicating specificity for anti-CPS IgG. The assay performance was examined in an interlaboratory study using residual sera from CPS-conjugate vaccine trials with international partners in the Group B Assay STandardisatiON (GASTON) Consortium. Strong correlations of reported titers between laboratories were observed: ST-Ia r = 0.88, ST-Ib r = 0.91, ST-II r = 0.91, ST-III r = 0.90 and ST-V r = 0.94. The OPKA is an easily transferable assay with accessible standard reagents and will be a valuable tool to assess GBS-specific antibodies in natural immunity and vaccine studies.
AbstractList The placental transfer of antibodies that mediate bacterial clearance via phagocytes is likely important for protection against invasive group B (GBS) disease. A robust functional assay is essential to determine the immune correlates of protection and assist vaccine development. Using standard reagents, we developed and optimized an opsonophagocytic killing assay (OPKA) where dilutions of test sera were incubated with bacteria, baby rabbit complement (BRC) and differentiated HL60 cells (dHL60) for 30 min. Following overnight incubation, the surviving bacteria were enumerated and the % bacterial survival was calculated relative to serum-negative controls. A reciprocal 50% killing titer was then assigned. The minimal concentrations of anti-capsular polysaccharide (CPS) IgG required for 50% killing were 1.65-3.70 ng/mL (depending on serotype). Inhibition of killing was observed using sera absorbed with homologous CPS but not heterologous CPS, indicating specificity for anti-CPS IgG. The assay performance was examined in an interlaboratory study using residual sera from CPS-conjugate vaccine trials with international partners in the Group B Assay STandardisatiON (GASTON) Consortium. Strong correlations of reported titers between laboratories were observed: ST-Ia r = 0.88, ST-Ib r = 0.91, ST-II r = 0.91, ST-III r = 0.90 and ST-V r = 0.94. The OPKA is an easily transferable assay with accessible standard reagents and will be a valuable tool to assess GBS-specific antibodies in natural immunity and vaccine studies.
The placental transfer of antibodies that mediate bacterial clearance via phagocytes is likely important for protection against invasive group B Streptococcus (GBS) disease. A robust functional assay is essential to determine the immune correlates of protection and assist vaccine development. Using standard reagents, we developed and optimized an opsonophagocytic killing assay (OPKA) where dilutions of test sera were incubated with bacteria, baby rabbit complement (BRC) and differentiated HL60 cells (dHL60) for 30 min. Following overnight incubation, the surviving bacteria were enumerated and the % bacterial survival was calculated relative to serum-negative controls. A reciprocal 50% killing titer was then assigned. The minimal concentrations of anti-capsular polysaccharide (CPS) IgG required for 50% killing were 1.65–3.70 ng/mL (depending on serotype). Inhibition of killing was observed using sera absorbed with homologous CPS but not heterologous CPS, indicating specificity for anti-CPS IgG. The assay performance was examined in an interlaboratory study using residual sera from CPS-conjugate vaccine trials with international partners in the Group B Streptococcus Assay STandardisatiON (GASTON) Consortium. Strong correlations of reported titers between laboratories were observed: ST-Ia r = 0.88, ST-Ib r = 0.91, ST-II r = 0.91, ST-III r = 0.90 and ST-V r = 0.94. The OPKA is an easily transferable assay with accessible standard reagents and will be a valuable tool to assess GBS-specific antibodies in natural immunity and vaccine studies.
The placental transfer of antibodies that mediate bacterial clearance via phagocytes is likely important for protection against invasive group B Streptococcus (GBS) disease. A robust functional assay is essential to determine the immune correlates of protection and assist vaccine development. Using standard reagents, we developed and optimized an opsonophagocytic killing assay (OPKA) where dilutions of test sera were incubated with bacteria, baby rabbit complement (BRC) and differentiated HL60 cells (dHL60) for 30 min. Following overnight incubation, the surviving bacteria were enumerated and the % bacterial survival was calculated relative to serum-negative controls. A reciprocal 50% killing titer was then assigned. The minimal concentrations of anti-capsular polysaccharide (CPS) IgG required for 50% killing were 1.65-3.70 ng/mL (depending on serotype). Inhibition of killing was observed using sera absorbed with homologous CPS but not heterologous CPS, indicating specificity for anti-CPS IgG. The assay performance was examined in an interlaboratory study using residual sera from CPS-conjugate vaccine trials with international partners in the Group B Streptococcus Assay STandardisatiON (GASTON) Consortium. Strong correlations of reported titers between laboratories were observed: ST-Ia r = 0.88, ST-Ib r = 0.91, ST-II r = 0.91, ST-III r = 0.90 and ST-V r = 0.94. The OPKA is an easily transferable assay with accessible standard reagents and will be a valuable tool to assess GBS-specific antibodies in natural immunity and vaccine studies.The placental transfer of antibodies that mediate bacterial clearance via phagocytes is likely important for protection against invasive group B Streptococcus (GBS) disease. A robust functional assay is essential to determine the immune correlates of protection and assist vaccine development. Using standard reagents, we developed and optimized an opsonophagocytic killing assay (OPKA) where dilutions of test sera were incubated with bacteria, baby rabbit complement (BRC) and differentiated HL60 cells (dHL60) for 30 min. Following overnight incubation, the surviving bacteria were enumerated and the % bacterial survival was calculated relative to serum-negative controls. A reciprocal 50% killing titer was then assigned. The minimal concentrations of anti-capsular polysaccharide (CPS) IgG required for 50% killing were 1.65-3.70 ng/mL (depending on serotype). Inhibition of killing was observed using sera absorbed with homologous CPS but not heterologous CPS, indicating specificity for anti-CPS IgG. The assay performance was examined in an interlaboratory study using residual sera from CPS-conjugate vaccine trials with international partners in the Group B Streptococcus Assay STandardisatiON (GASTON) Consortium. Strong correlations of reported titers between laboratories were observed: ST-Ia r = 0.88, ST-Ib r = 0.91, ST-II r = 0.91, ST-III r = 0.90 and ST-V r = 0.94. The OPKA is an easily transferable assay with accessible standard reagents and will be a valuable tool to assess GBS-specific antibodies in natural immunity and vaccine studies.
Author Le Doare, Kirsty
Taylor, Stephen
Kwatra, Gaurav
Gorringe, Andrew
Patel, Palak Y
Collett, Clare F
Leung, Stephanie
Bolcen, Shanna J
Allen, Lauren
Thomas, Stephen
Hall, Tom
Lim, Suzanna
Alston, Bailey
Maniatis, Pete
Author_xml – sequence: 1
  givenname: Stephanie
  orcidid: 0000-0002-8880-2977
  surname: Leung
  fullname: Leung, Stephanie
  organization: UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK
– sequence: 2
  givenname: Clare F
  orcidid: 0000-0002-8878-2873
  surname: Collett
  fullname: Collett, Clare F
  organization: UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK
– sequence: 3
  givenname: Lauren
  surname: Allen
  fullname: Allen, Lauren
  organization: UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK
– sequence: 4
  givenname: Suzanna
  surname: Lim
  fullname: Lim, Suzanna
  organization: Maternal and Neonatal Vaccine Immunology Research Group, Centre for Neonatal and Paediatric Infection, St George's, University of London, London SW17 0RE, UK
– sequence: 5
  givenname: Pete
  orcidid: 0000-0001-5240-0848
  surname: Maniatis
  fullname: Maniatis, Pete
  organization: Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
– sequence: 6
  givenname: Shanna J
  orcidid: 0000-0002-7464-9967
  surname: Bolcen
  fullname: Bolcen, Shanna J
  organization: Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
– sequence: 7
  givenname: Bailey
  surname: Alston
  fullname: Alston, Bailey
  organization: Eagle Global Scientific, Atlanta, GA 30341, USA
– sequence: 8
  givenname: Palak Y
  surname: Patel
  fullname: Patel, Palak Y
  organization: Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
– sequence: 9
  givenname: Gaurav
  surname: Kwatra
  fullname: Kwatra, Gaurav
  organization: Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
– sequence: 10
  givenname: Tom
  orcidid: 0000-0002-9001-6684
  surname: Hall
  fullname: Hall, Tom
  organization: Maternal and Neonatal Vaccine Immunology Research Group, Centre for Neonatal and Paediatric Infection, St George's, University of London, London SW17 0RE, UK
– sequence: 11
  givenname: Stephen
  orcidid: 0000-0003-2368-8058
  surname: Thomas
  fullname: Thomas, Stephen
  organization: UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK
– sequence: 12
  givenname: Stephen
  surname: Taylor
  fullname: Taylor, Stephen
  organization: UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK
– sequence: 13
  givenname: Kirsty
  orcidid: 0000-0002-5104-085X
  surname: Le Doare
  fullname: Le Doare, Kirsty
  organization: Maternal and Neonatal Vaccine Immunology Research Group, Centre for Neonatal and Paediatric Infection, St George's, University of London, London SW17 0RE, UK
– sequence: 14
  givenname: Andrew
  surname: Gorringe
  fullname: Gorringe, Andrew
  organization: UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38006035$$D View this record in MEDLINE/PubMed
BookMark eNpdkcFvFCEUh4mpsbX27smQePGy-oCBgeNatW5s0oOaeJswzJuVzSyMMNNkvfYfL7tbG9N3gbx8v-9B3ktyEmJAQl4zeC-EgQ-31jkfMLN91SCekTMOtVoII36d_Hc_JRc5b6CUYUKr-gU5FRpAgZBn5O4T3uIQxy2GicaeLun3yYbOps7_xY7ejDmGOP626-h2U8w-029-GHxY02XOdkf7mOhVivNIP5ZkwnGKLjo3Z1osewZzPrh9KB26ChOmwbYx2SmmXYnM3e4Ved7bIePFw3lOfn75_OPy6-L65mp1ubxeOKH1tLAAFbZMW6W0rK2SIKWCrsNKCwaiMhYY1qZXnLetdjUqaF0FvQPBTVdbcU5WR28X7aYZk9_atGui9c2hEdO6sWnybsCGS0CUvGeWu6rXZSyTfS0BWCsNQ1Vc746uMcU_M-ap2frscBhswDjnhmsjdFVxZQr69gm6iXMK5acHSshKGV4oOFIuxZwT9o8PZNDs99083XeJvHkQz-0Wu8fAv-2Ke-4Bqe8
Cites_doi 10.1128/CDLI.10.6.1019-1024.2003
10.1086/342411
10.1016/j.isci.2023.106261
10.1016/j.jim.2012.01.011
10.3201/eid1904.121572
10.1016/j.vaccine.2007.01.119
10.1128/cdli.4.4.415-422.1997
10.1128/IAI.69.11.6696-6701.2001
10.1093/infdis/140.6.1004
10.3346/jkms.2018.33.e127
10.1016/S1473-3099(18)30659-5
10.1016/S1473-3099(20)30478-3
10.1016/j.vaccine.2016.12.029
10.1097/MOP.0000000000001223
10.1086/382193
10.1093/infdis/173.1.142
10.1097/INF.0000000000002328
10.1016/j.vaccine.2006.07.018
10.1186/1471-2334-10-60
10.1128/mSphere.00070-18
10.1016/S1473-3099(14)70822-9
10.1080/14760584.2021.1940144
10.1080/21645515.2022.2037350
10.3389/fimmu.2018.02674
10.1128/JCM.01128-15
10.1016/j.vaccine.2009.05.039
10.1007/s10156-013-0601-1
10.1016/S0264-410X(03)00230-5
10.4161/hv.8376
10.7883/yoken.66.158
10.1080/21645515.2017.1377379
10.3390/vaccines11020357
10.1128/CVI.00086-12
10.1016/S0264-410X(00)00044-X
10.1128/CVI.00370-10
10.1086/314574
10.1046/j.1442-200X.2002.01638.x
10.1086/315839
10.1016/j.vaccine.2019.04.039
10.1086/375536
ContentType Journal Article
Copyright 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID NPM
AAYXX
CITATION
3V.
7T7
7XB
8FD
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
P64
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
DOA
DOI 10.3390/vaccines11111703
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Engineering Research Database
ProQuest Central Student
Research Library Prep
SciTech Premium Collection
Biological Sciences
ProQuest research library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Technology Research Database
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Coronavirus Research Database
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Publicly Available Content Database
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
Medicine
EISSN 2076-393X
ExternalDocumentID oai_doaj_org_article_250ee52f1a2c4f8eb115f75001b591e6
10_3390_vaccines11111703
38006035
Genre Journal Article
GeographicLocations Denmark
Canada
United Kingdom--UK
United States--US
GeographicLocations_xml – name: Denmark
– name: Canada
– name: United Kingdom--UK
– name: United States--US
GroupedDBID 3V.
53G
5VS
8FE
8FH
8G5
AADQD
AAHBH
ABUWG
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
DIK
DWQXO
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
NPM
OK1
PGMZT
PIMPY
PQQKQ
PROAC
RNS
RPM
AAYXX
CITATION
7T7
7XB
8FD
8FK
C1K
COVID
FR3
MBDVC
P64
PQEST
PQUKI
PRINS
Q9U
RIG
7X8
ID FETCH-LOGICAL-c388t-a004eb18a66857a6505560dde48310349a01e79f622bb8c7e60bc40fc0329d7a3
IEDL.DBID M48
ISSN 2076-393X
IngestDate Tue Oct 22 15:09:52 EDT 2024
Thu Dec 05 22:20:28 EST 2024
Thu Oct 10 19:27:15 EDT 2024
Fri Dec 06 02:45:38 EST 2024
Sun Dec 08 01:35:49 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords correlates of protection
OPKA
vaccines
Group B Streptococcus
opsonophagocytosis assay
transplacental antibodies
neonatal antibodies
Language English
License https://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c388t-a004eb18a66857a6505560dde48310349a01e79f622bb8c7e60bc40fc0329d7a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-8880-2977
0000-0002-5104-085X
0000-0002-7464-9967
0000-0002-8878-2873
0000-0003-2368-8058
0000-0001-5240-0848
0000-0002-9001-6684
OpenAccessLink https://doaj.org/article/250ee52f1a2c4f8eb115f75001b591e6
PMID 38006035
PQID 2893354692
PQPubID 2032320
ParticipantIDs doaj_primary_oai_doaj_org_article_250ee52f1a2c4f8eb115f75001b591e6
proquest_miscellaneous_2893844269
proquest_journals_2893354692
crossref_primary_10_3390_vaccines11111703
pubmed_primary_38006035
PublicationCentury 2000
PublicationDate 2023-Nov-09
PublicationDateYYYYMMDD 2023-11-09
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-Nov-09
  day: 09
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Vaccines (Basel)
PublicationTitleAlternate Vaccines (Basel)
PublicationYear 2023
Publisher MDPI AG
Publisher_xml – name: MDPI AG
References Kobayashi (ref_10) 2019; 37
Matsubara (ref_32) 2002; 186
Vekemans (ref_2) 2019; 37
Teatero (ref_30) 2015; 53
Lee (ref_15) 2018; 33
Choi (ref_13) 2018; 14
ref_36
Nahm (ref_26) 2000; 18
Paul (ref_1) 2023; 35
Baker (ref_19) 2000; 182
Davies (ref_3) 2019; 38
Andrews (ref_34) 2014; 14
Absalon (ref_4) 2021; 21
Absalon (ref_6) 2022; 18
Findlow (ref_8) 2022; 21
Baker (ref_18) 2003; 188
Kimura (ref_31) 2013; 66
Ferrieri (ref_29) 2013; 19
Pawlowski (ref_5) 2023; 26
Song (ref_37) 2013; 19
ref_25
Paoletti (ref_21) 2001; 69
Frasch (ref_38) 2003; 10
Guttormsen (ref_23) 1996; 173
Libutti (ref_24) 1997; 4
Pannaraj (ref_16) 2009; 27
Baker (ref_20) 2004; 189
Siber (ref_35) 2007; 25
Edwards (ref_12) 1979; 140
Burton (ref_27) 2012; 19
Butler (ref_7) 2003; 21
Fabbrini (ref_14) 2012; 378
Kampmann (ref_9) 2019; 19
Baker (ref_22) 2007; 25
Baker (ref_17) 1999; 179
Rose (ref_39) 2011; 18
Balloch (ref_40) 2018; 3
Guttormsen (ref_28) 2009; 5
Hoshina (ref_33) 2002; 44
Sadarangani (ref_11) 2018; 9
References_xml – volume: 10
  start-page: 1019
  year: 2003
  ident: ref_38
  article-title: Multilaboratory Evaluation of a Viability Assay for Measurement of Opsonophagocytic Antibodies Specific to the Capsular Polysaccharides of Streptococcus pneumoniae
  publication-title: Clin. Vaccine Immunol.
  doi: 10.1128/CDLI.10.6.1019-1024.2003
  contributor:
    fullname: Frasch
– volume: 186
  start-page: 855
  year: 2002
  ident: ref_32
  article-title: Seroepidemiologic Studies of Serotype VIII Group B Streptococcus in Japan
  publication-title: J. Infect. Dis.
  doi: 10.1086/342411
  contributor:
    fullname: Matsubara
– volume: 26
  start-page: 106261
  year: 2023
  ident: ref_5
  article-title: Safety and Immunogenicity of the Group B Streptococcus Vaccine AlpN in a Placebo-Controlled Double-Blind Phase 1 Trial
  publication-title: iScience
  doi: 10.1016/j.isci.2023.106261
  contributor:
    fullname: Pawlowski
– volume: 378
  start-page: 11
  year: 2012
  ident: ref_14
  article-title: A New Flow-Cytometry-Based Opsonophagocytosis Assay for the Rapid Measurement of Functional Antibody Levels against Group B Streptococcus
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2012.01.011
  contributor:
    fullname: Fabbrini
– volume: 19
  start-page: 553
  year: 2013
  ident: ref_29
  article-title: Serotype IV and Invasive Group B Streptococcus Disease in Neonates, Minnesota, USA, 2000–2001
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid1904.121572
  contributor:
    fullname: Ferrieri
– volume: 25
  start-page: 3816
  year: 2007
  ident: ref_35
  article-title: Estimating the Protective Concentration of Anti-Pneumococcal Capsular Polysaccharide Antibodies
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2007.01.119
  contributor:
    fullname: Siber
– volume: 4
  start-page: 415
  year: 1997
  ident: ref_24
  article-title: Standardization of an Opsonophagocytic Assay for the Measurement of Functional Antibody Activity against Streptococcus pneumoniae Using Differentiated HL-60 Cells
  publication-title: Clin. Diagn. Lab. Immunol.
  doi: 10.1128/cdli.4.4.415-422.1997
  contributor:
    fullname: Libutti
– volume: 69
  start-page: 6696
  year: 2001
  ident: ref_21
  article-title: Effects of Alum Adjuvant or a Booster Dose on Immunogenicity during Clinical Trials of Group B Streptococcal Type III Conjugate Vaccines
  publication-title: Infect. Immun.
  doi: 10.1128/IAI.69.11.6696-6701.2001
  contributor:
    fullname: Paoletti
– volume: 140
  start-page: 1004
  year: 1979
  ident: ref_12
  article-title: Opsonic Specificity of Human Antibody to the Type III Polysaccharide of Group B Streptococcus
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/140.6.1004
  contributor:
    fullname: Edwards
– volume: 33
  start-page: e127
  year: 2018
  ident: ref_15
  article-title: Seroprevalence of Opsonophagocytic Antibodies against Serotype Ia, Ib, II, III, and V Group B Streptococcus among Korean Population
  publication-title: J. Korean Med. Sci.
  doi: 10.3346/jkms.2018.33.e127
  contributor:
    fullname: Lee
– volume: 19
  start-page: e162
  year: 2019
  ident: ref_9
  article-title: Serocorrelates of Protection against Infant Group B Streptococcus Disease
  publication-title: Lancet Infect Dis.
  doi: 10.1016/S1473-3099(18)30659-5
  contributor:
    fullname: Kampmann
– volume: 21
  start-page: 263
  year: 2021
  ident: ref_4
  article-title: Safety and Immunogenicity of a Novel Hexavalent Group B Streptococcus Conjugate Vaccine in Healthy, Non-Pregnant Adults: A Phase 1/2, Randomised, Placebo-Controlled, Observer-Blinded, Dose-Escalation Trial
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(20)30478-3
  contributor:
    fullname: Absalon
– volume: 37
  start-page: 7307
  year: 2019
  ident: ref_10
  article-title: WHO Consultation on Group B Streptococcus Vaccine Development: Report from a Meeting Held on 27–28 April 2016
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.12.029
  contributor:
    fullname: Kobayashi
– volume: 35
  start-page: 223
  year: 2023
  ident: ref_1
  article-title: 20 Million Pregnant Women with Group B Streptococcus Carriage: Consequences, Challenges, and Opportunities for Prevention
  publication-title: Curr. Opin. Pediatr.
  doi: 10.1097/MOP.0000000000001223
  contributor:
    fullname: Paul
– volume: 189
  start-page: 1103
  year: 2004
  ident: ref_20
  article-title: Immune Response of Healthy Women to 2 Different Group B Streptococcal Type V Capsular Polysaccharide-Protein Conjugate Vaccines
  publication-title: J. Infect. Dis.
  doi: 10.1086/382193
  contributor:
    fullname: Baker
– volume: 173
  start-page: 142
  year: 1996
  ident: ref_23
  article-title: Quantitative Determination of Antibodies to Type III Group B Streptococcal Polysaccharide
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/173.1.142
  contributor:
    fullname: Guttormsen
– volume: 38
  start-page: S72
  year: 2019
  ident: ref_3
  article-title: Group B Streptococcus: Trials and Tribulations
  publication-title: Pediatr. Infect. Dis. J.
  doi: 10.1097/INF.0000000000002328
  contributor:
    fullname: Davies
– volume: 25
  start-page: 55
  year: 2007
  ident: ref_22
  article-title: Dose–Response to Type V Group B Streptococcal Polysaccharide–Tetanus Toxoid Conjugate Vaccine in Healthy Adults
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.07.018
  contributor:
    fullname: Baker
– ident: ref_36
  doi: 10.1186/1471-2334-10-60
– volume: 3
  start-page: e00070-18
  year: 2018
  ident: ref_40
  article-title: Interlaboratory Comparison of the Pneumococcal Multiplex Opsonophagocytic Assays and Their Level of Agreement for Determination of Antibody Function in Pediatric Sera
  publication-title: mSphere
  doi: 10.1128/mSphere.00070-18
  contributor:
    fullname: Balloch
– volume: 14
  start-page: 839
  year: 2014
  ident: ref_34
  article-title: Serotype-Specific Effectiveness and Correlates of Protection for the 13-Valent Pneumococcal Conjugate Vaccine: A Postlicensure Indirect Cohort Study
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(14)70822-9
  contributor:
    fullname: Andrews
– volume: 21
  start-page: 739
  year: 2022
  ident: ref_8
  article-title: Correlates of Protection for Meningococcal Surface Protein Vaccines: Lessons from the Past
  publication-title: Expert Rev. Vaccines
  doi: 10.1080/14760584.2021.1940144
  contributor:
    fullname: Findlow
– volume: 18
  start-page: 2037350
  year: 2022
  ident: ref_6
  article-title: Advances towards Licensure of a Maternal Vaccine for the Prevention of Invasive Group B Streptococcus Disease in Infants: A Discussion of Different Approaches
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2022.2037350
  contributor:
    fullname: Absalon
– volume: 9
  start-page: 2674
  year: 2018
  ident: ref_11
  article-title: Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.02674
  contributor:
    fullname: Sadarangani
– volume: 53
  start-page: 2919
  year: 2015
  ident: ref_30
  article-title: Emergence of Serotype IV Group B Streptococcus Adult Invasive Disease in Manitoba and Saskatchewan, Canada, Is Driven by Clonal Sequence Type 459 Strains
  publication-title: J. Clin. Microbiol.
  doi: 10.1128/JCM.01128-15
  contributor:
    fullname: Teatero
– volume: 27
  start-page: 4452
  year: 2009
  ident: ref_16
  article-title: Group B Streptococcal Conjugate Vaccines Elicit Functional Antibodies Independent of Strain O-Acetylation
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.05.039
  contributor:
    fullname: Pannaraj
– volume: 19
  start-page: 412
  year: 2013
  ident: ref_37
  article-title: Pneumococcal Vaccine and Opsonic Pneumococcal Antibody
  publication-title: J. Infect. Chemother.
  doi: 10.1007/s10156-013-0601-1
  contributor:
    fullname: Song
– volume: 21
  start-page: 3265
  year: 2003
  ident: ref_7
  article-title: Serological Criteria for Evaluation and Licensure of New Pneumococcal Conjugate Vaccine Formulations for Use in Infants
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(03)00230-5
  contributor:
    fullname: Butler
– volume: 5
  start-page: 461
  year: 2009
  ident: ref_28
  article-title: A Fluorescence-Based Opsonophagocytosis Assay to Measure the Functional Activity of Antibody to Group B Streptococcus
  publication-title: Hum. Vaccin.
  doi: 10.4161/hv.8376
  contributor:
    fullname: Guttormsen
– volume: 66
  start-page: 158
  year: 2013
  ident: ref_31
  article-title: Active Screening of Group B Streptococci with Reduced Penicillin Susceptibility and Altered Serotype Distribution Isolated from Pregnant Women in Kobe, Japan
  publication-title: Jpn. J. Infect. Dis.
  doi: 10.7883/yoken.66.158
  contributor:
    fullname: Kimura
– volume: 14
  start-page: 67
  year: 2018
  ident: ref_13
  article-title: Development of a Multiplexed Opsonophagocytic Killing Assay (MOPA) for Group B Streptococcus
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2017.1377379
  contributor:
    fullname: Choi
– ident: ref_25
  doi: 10.3390/vaccines11020357
– volume: 19
  start-page: 835
  year: 2012
  ident: ref_27
  article-title: Development of a Fourfold Multiplexed Opsonophagocytosis Assay for Pneumococcal Antibodies against Additional Serotypes and Discovery of Serological Subtypes in Streptococcus pneumoniae Serotype 20
  publication-title: Clin. Vaccine Immunol.
  doi: 10.1128/CVI.00086-12
  contributor:
    fullname: Burton
– volume: 18
  start-page: 2768
  year: 2000
  ident: ref_26
  article-title: Development of a Multi-Specificity Opsonophagocytic Killing Assay
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(00)00044-X
  contributor:
    fullname: Nahm
– volume: 18
  start-page: 135
  year: 2011
  ident: ref_39
  article-title: Multilaboratory Comparison of Streptococcus pneumoniae Opsonophagocytic Killing Assays and Their Level of Agreement for the Determination of Functional Antibody Activity in Human Reference Sera
  publication-title: Clin. Vaccine Immunol.
  doi: 10.1128/CVI.00370-10
  contributor:
    fullname: Rose
– volume: 179
  start-page: 142
  year: 1999
  ident: ref_17
  article-title: Safety and Immunogenicity of Capsular Polysaccharide—Tetanus Toxoid Conjugate Vaccines for Group B Streptococcal Types Ia and Ib
  publication-title: J. Infect. Dis.
  doi: 10.1086/314574
  contributor:
    fullname: Baker
– volume: 44
  start-page: 641
  year: 2002
  ident: ref_33
  article-title: Trend of Neonatal Group B Streptococcal Infection during the Last 15 Years
  publication-title: Pediatr. Int.
  doi: 10.1046/j.1442-200X.2002.01638.x
  contributor:
    fullname: Hoshina
– volume: 182
  start-page: 1129
  year: 2000
  ident: ref_19
  article-title: Use of Capsular Polysaccharide—Tetanus Toxoid Conjugate Vaccine for Type II Group B Streptococcus in Healthy Women
  publication-title: J. Infect. Dis.
  doi: 10.1086/315839
  contributor:
    fullname: Baker
– volume: 37
  start-page: 3190
  year: 2019
  ident: ref_2
  article-title: The Role of Immune Correlates of Protection on the Pathway to Licensure, Policy Decision and Use of Group B Streptococcus Vaccines for Maternal Immunization: Considerations from World Health Organization Consultations
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2019.04.039
  contributor:
    fullname: Vekemans
– volume: 188
  start-page: 66
  year: 2003
  ident: ref_18
  article-title: Safety and Immunogenicity of a Bivalent Group B Streptococcal Conjugate Vaccine for Serotypes II and III
  publication-title: J. Infect. Dis.
  doi: 10.1086/375536
  contributor:
    fullname: Baker
SSID ssj0000913867
Score 2.3079698
Snippet The placental transfer of antibodies that mediate bacterial clearance via phagocytes is likely important for protection against invasive group B (GBS) disease....
The placental transfer of antibodies that mediate bacterial clearance via phagocytes is likely important for protection against invasive group B Streptococcus...
SourceID doaj
proquest
crossref
pubmed
SourceType Open Website
Aggregation Database
Index Database
StartPage 1703
SubjectTerms Animal vaccines
Antibodies
Assaying
Bacteria
Capsular polysaccharides
Cell differentiation
Consortia
correlates of protection
Flow cytometry
Group B Streptococcus
Immune clearance
Immunoassay
Immunoglobulin G
Licenses
Medical schools
Medicine
Monoclonal antibodies
neonatal antibodies
OPKA
Opsonophagocytosis
opsonophagocytosis assay
Phagocytes
Placental transfer
Polysaccharides
R&D
Reagents
Research & development
Standardization
Streptococcus
Streptococcus infections
Vaccine development
Vaccines
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na9RAFB-kJy_iR9XYKk-QgtDQJPN93EpLqaAFW-gtTCYzupdkabJCvPqP-2Ymu12E4sXr5IPhfb95b36PkA9Gaumt4HlpnclZ6YtcG8fzQtgWwwVamoT2-UVc3LDLW367M-or9IQleOBEuBN00c7xyuNHlnmFpqXkHt1cUTZcly6BbRfVTjIVbbAuqRIy1SUp5vUnP40NleohmIhSbmZkzX4owvU_HGNGX3P-lDyZg0RYpM09I49c95wcXSWU6ekYru8vTQ3HcARX9_jT0wvye6cRCHoPC_g2nxcsf7kWvob-j371w3zv7TT2w3KAz8uIzA3IKzMBhrEQj6TgFELRejX2aDXtegD8Cyy2UJ6w7HAF4pniLEv93QShM3HaJzfnZ9efLvJ51kJuqVJjblBZkLbKCKG4NBi3cYyF0PaxOImMaVOUTmovqqpplJVOFI1lhbcFrXQrDX1J9rq-c68JWKQ008r6SkjmUb-NZy3zzLZMoVS0Gfm4oXy9SpAaNaYigUv131zKyGlgzfa9AIYdF1BE6llE6n-JSEYON4ytZw0dakw0KeVM6Coj77ePUbdCwcR0rl-ndxQLl30z8ioJxHYnVAUoG8rf_I8dHpDHYYx9vOOoD8neeLd2bzHYGZt3Ua7_AA-P_xI
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Coronavirus Research Database
  dbid: COVID
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9UwFA-6gfjix_yqTjmCDIR160eSpk9yNx1T0Q3cZG8lTZN5EZrrba_QvfqPe9KmvTLQB1_TEhLyy8kv55z8DiGvZJZnRnEWxkrLkMYmCnOpWRhxVSFdSGM5qH1-5sfn9MMFu_AOt8anVY42sTfUlVXOR76fuLrwDC9zyZvFj9BVjXLRVV9C4ybZTJE6IMI3D0--vn87eVmc6qXg2RCfTPF-v_9TKhexbpypiLOxVpY_j3rZ_r9zzf7MObpLinG0Q6rJ971VW-6pq2tCjv8_nXvkjqejMBvwc5_c0PUWufXJB9y3yM7pIG3d7cLZ-qVWsws7cLoWve4ekF9_ZB-BNTCDL95JMb_SFZy4pBO7-CYvrepa28wb-Djv5cABASI7QO4MvR8MDsBFyhetRVOtVg1gLzCb9ENhXmML9I5MD2C77MClQ3YPyfnRu7PD49AXeAhVKkQbStyheFYIyblgmUSyyJCAocGlffkzmsso1llueJKUpVCZ5lGpaGRUlCZ5lcn0Edmoba2fEFC4rDQXyiQ8owaNijS0ooaqigqEYhWQ1-MyF4tBx6PA-4-DRHEdEgE5cDiY_nMK3H2DXV4WfkMXSB21ZolBMCtqBE4jZgbpVxSXLI81D8j2uPCFNwtNsV71gLycPuOGdlEaWWu7Gv4R1L0wDsjjAX3TSFLh9HNS9vTfnT8jtxPkYv2TyXybbLTLlX6O3KktX_gN8ht5ih6q
  priority: 102
  providerName: ProQuest
Title Development of A Standardized Opsonophagocytosis Killing Assay for Group B Streptococcus and Assessment in an Interlaboratory Study
URI https://www.ncbi.nlm.nih.gov/pubmed/38006035
https://www.proquest.com/docview/2893354692
https://www.proquest.com/docview/2893844269
https://doaj.org/article/250ee52f1a2c4f8eb115f75001b591e6
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Nb9MwFLfQduGC-KYwqoeEJiEtkMR2Yh8QasemAWKrYEW9RY5jj0pT0jUpIlz5x3l20hbQOHCK5FhW4vfh37P9fo-Q5yqVqdUJDyJtVMAiGwZSGR6EiS4QLtBIdWyfp8nJlL2f8dk2PbqfwPra0M7Vk5ouL19-v2rfoMG_dhEnhuyvvintDqFrZ_1R6qg_d2NcF90Fr4892Pd-WUZU-JKyMQbvAZV01p1bXjvIH-uUp_P_Nwb1a9HxbXKrB5Ew6qR-h9ww5V2yP-lYqNsDON8mVdUHsA-TLT91e4_8_O2iEFQWRvC530-Y_zAFnLn7IdXiq7qodNtU9byGD3PP3A0oS9UCwlzwW1YwBneovWgq9Kp6VQOOAqMN1SfMS2wBv-fY61q1bMHdXGzvk-nx0fnhSdDXYgg0FaIJFBoTunWhkkTwVCGu44iV0DcyX6mMSRVGJpU2ieM8Fzo1SZhrFlod0lgWqaIPyE5ZleYRAY0zzaTQNk5SZtH-lWUFs0wXTKDWFAPyYj3z2aKj3MgwVHFSyv6W0oCMnWg2_RxZtm-olhdZb3sZojxjeGxR7zSzAn8j4haRUhjlXEYmGZC9tWCztQJmGIhSylki4wF5tnmNtucOVFRpqlXXRzCXDDwgDzuF2HwJFY7qhvLH__E3T8hNV83epzrKPbLTLFfmKWKeJh-S3fHR6eQTPg_Pvrx7O_R7B0Ov4L8AXK8FuQ
link.rule.ids 314,780,784,864,2102,2221,21388,24318,27924,27925,33744,33745,38516,43805,43895,74302,74412
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7BVgIuPMqjgQJGQpWQmjYPO3FOaFuotvQpsUW9RY5jtyukZNlkkdIrf5xx4mRRJThwdSLLlj-PP8-MvwF4L-Ik1jJiri-VcKmvPTcRirleJHOkC6EvOrXP02hyQb9cskvrcKtsWmVvE1tDnZfS-Mh3A1MXnuFlLvg4_-GaqlEmumpLaNyFNVPFm41gbf_s2-GnwctiVC95FHfxyRDv97s_hTQR68qYCj_ua2XZ86iV7f8712zPnINHkPaj7VJNvu8s62xH3twScvz_6TyGh5aOknGHnydwRxXrcO_EBtzXYeu8k7Zutsl09VKr2iZb5Hwlet08hV9_ZB-RUpMx-WqdFLMblZMzk3RSzq_FVSmbuqxmFTmatXLgBAEiGoLcmbR-MLJHTKR8XpdoquWyItgLGQ_6oWRWYAtpHZkWwOWiISYdsnkGFwefp_sT1xZ4cGXIee0K3KF4VnARRZzFAskiQwKGBpe25c9oIjxfxYmOgiDLuIxV5GWSelp6YZDksQifw6goC7UBROKy0oRLHUQx1WhUhKY51VTmlCMUcwc-9MuczjsdjxTvPwYS6W1IOLBncDD8ZxS424ZycZXaDZ0idVSKBRrBLKnmOA2faaRfnp-xxFeRA5v9wqfWLFTpatUdeDd8xg1tojSiUOWy-4dT88LYgRcd-oaRhNzo54Ts5b87fwv3J9OT4_T48PToFTwIkJe1zyeTTRjVi6V6jTyqzt7YzfIbHDEhmg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegkyZe0BgfCxtwSGgS0qLmw3acJ9TCqsGgVLBJe4scxx59SUqTIoVX_nHOiZsiJHh1LCvJffjnu_PvCHklkzQxijM_VFr6NDSBn0rN_ICrAuFCHMqe7XPOL67phxt24-qfaldWufWJnaMuKmVj5OPI9oVneJiLxsaVRSzezd6svvu2g5TNtLp2GnfJHu6KQTQie9Pz-eLLEHGxDJiCJ32uMsaz_viHVDZ7XVu3ESbbvllub-oo_P-NO7v9Z3ZA7jvgCJNe0g_IHV0ekv1PLjV-SE4XPQl1ewZXuztV9RmcwmJHT90-JL_-qBOCysAEvrpwwvKnLuCzLQ-pVt_kbaXapqqXNVwuO-JuQFHKFhDlQhexginYnPaqqdCpqk0NuApMBqZPWJY4Al3I0alatW7BFi62j8j17Pzq7YXvWjH4Khai8SXaEnp1ITkXLJEI6xhCJXSNtGtURlMZhDpJDY-iPBcq0TzIFQ2MCuIoLRIZPyajsir1EQGFP52mQpmIJ9Sg-UtDC2qoKqhApSk88norhGzVM25keFKxAsv-FphHplZKwzzLld0NVOvbzJlehiBPaxYZVDtFjcDPCJlBoBSEOUtDzT1yspVx5gy4znbq5pGXw2M0PZtPkaWuNv0cQe1dYI886XVjeJNYWKabmD39_-IvyD5qcfbx_fzymNyzrey7e47pCRk1641-hoCnyZ87Tf4NS3wC0w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+A+Standardized+Opsonophagocytosis+Killing+Assay+for+Group+B+Streptococcus+and+Assessment+in+an+Interlaboratory+Study&rft.jtitle=Vaccines+%28Basel%29&rft.au=Leung%2C+Stephanie&rft.au=Collett%2C+Clare+F.&rft.au=Allen%2C+Lauren&rft.au=Lim%2C+Suzanna&rft.date=2023-11-09&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=11&rft.issue=11&rft.spage=1703&rft_id=info:doi/10.3390%2Fvaccines11111703&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_vaccines11111703
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon